ArticleJournal of oncology2022
Development of a Novel Immune Subtyping System Expanded with Immune Landscape and an 11-Gene Signature for Predicting Prostate Cancer Survival.
Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNearly half of patients with prostate cancer will develop metastasis. Immunotherapy is currently a promising strategy for treating metastatic prostate cancer. This study aimed to construct an immune subtyping system and provide a more comprehensive understanding of tumor microenvironment.
methodsData were downloaded from TCGA database and cBioPortal database. Consensus clustering was used to identify immune subtypes. Immune features were scored by ESTIMATE and CIBERSORT. Efficacy of different subtypes in immunotherapy was predicted by TIDE tool. Immune landscape was delineated through "monocle." Coexpressed gene modules were identified by weighted correlation network analysis. Univariate Cox regression analysis and LASSO analysis were applied to construct a prognostic model.
resultsFour immune subtypes (IS1 to IS4) were identified. Prognosis, mutation patterns, expression of immune genes, immune biomarkers, immunohistochemical biomarkers, and prediction efficacy of immunotherapy were significantly different among four immune subtypes. Five coexpressed gene modules were identified and an 11-gene prognostic model was constructed based on the modules.
conclusionsThe study developed a novel immune subtyping system and an 11-gene prognostic model of prostate cancer, which could guide personalized treatment and immunotherapy for patients with prostate cancer.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.